Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ATR-101 (Nevanimibe hydrochloride) in Endogenous Cushing's Syndrome
2016-002240-17Phase 2Terminated
- Sponsor
- Millendo Therapeutics
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cushing's syndrome comparing Nevanimibe hydrochloride with Placebo (2 arms). Started Mar 2017; status: terminated.
02
Drugs
Nevanimibe
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2016-002240-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002240-17.